Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 3/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952333 | 1.00 | TSHR (0.52) | TSHRHSD17B10ALDH1A1CYP3A4TDP1 | |
| SCHEMBL24165 | 0.81 | TTR (0.57) | TSHRHSD17B10ALDH1A1TTRENPP2 | |
| SCHEMBL130450 | 0.80 | TTR (0.61) | TSHRHSD17B10CYP3A4TTRENPP2 | |
| SCHEMBL1277359 | 0.77 | ENPP2 (0.50) | TSHRALDH1A1TTRENPP2CA1 | |
| SCHEMBL24730423 | 0.74 | TTR (0.50) | TSHRALDH1A1TTRENPP2CA1 | |
| SCHEMBL177405 | 0.74 | TTR (0.50) | TTRENPP2CA1CA2 | |
| SCHEMBL29427126 | 0.74 | TTR (0.50) | TTRENPP2CA1CA2 | |
| SCHEMBL1529238 | 0.74 | CA1 (0.52) | TSHRALDH1A1TTRENPP2CA1 | |
| SCHEMBL310780 | 0.74 | TTR (0.50) | TSHRTTRENPP2CA1CA2 | |
| SCHEMBL29465759 | 0.74 | TTR (0.50) | TSHRTTRENPP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184818-A | Functionalized high molecular polymer, visualized embolism microsphere prepared by microfluidic technology and application | 四川大学 | 2024-06-14 | — | — | CN | claimed |
| CN-114585396-A | Injectable hydrogel with anti-inflammatory and repair promoting functions, preparation method thereof and application thereof in heart repair | 四川大学 | 2022-06-03 | — | — | CN | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| CN-118290386-A | 7-Hydroxyflavone compound, and preparation method and application thereof | 国科大杭州高等研究院 | 2024-07-05 | — | — | CN | disclosed |
| CN-118184818-A | Functionalized high molecular polymer, visualized embolism microsphere prepared by microfluidic technology and application | 四川大学 | 2024-06-14 | — | — | CN | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-116785228-A | Multi-functional injectable hydrogel with microenvironment response as well as preparation method and application thereof | 四川大学 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| CN-114099416-B | Multifunctional injectable hydrogel with micro-environment response function and preparation method and application thereof | 四川大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013148603-A1 | CINNOLINE DERIVATIVES AS AS BTK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013134415-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | TPMT, TYMP, HPRT1 | TSHR 2770/4885HSD17B10 2013/4885ALDH1A1 609/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | TSHR 4585/4885HSD17B10 638/4885ALDH1A1 1260/4885 |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | TSHR 4513/4885HSD17B10 3333/4885ALDH1A1 1603/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | TSHR 179/4885HSD17B10 1729/4885ALDH1A1 1841/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | TSHR 1803/4885HSD17B10 1308/4885ALDH1A1 240/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | TSHR 2304/4885HSD17B10 3903/4885ALDH1A1 2833/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | TSHR 1899/4885HSD17B10 3249/4885ALDH1A1 2777/4885 |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | FAH, SLC10A1, OAT | TSHR 3019/4885HSD17B10 43/4885ALDH1A1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.